بدائل البحث:
significant decrease » significantly increased (توسيع البحث)
significant rates » significant facies (توسيع البحث), significant role (توسيع البحث), significant risks (توسيع البحث)
rates decrease » rate decreased (توسيع البحث), greatest decrease (توسيع البحث), greater decrease (توسيع البحث)
significant decrease » significantly increased (توسيع البحث)
significant rates » significant facies (توسيع البحث), significant role (توسيع البحث), significant risks (توسيع البحث)
rates decrease » rate decreased (توسيع البحث), greatest decrease (توسيع البحث), greater decrease (توسيع البحث)
-
1841
-
1842
-
1843
-
1844
-
1845
-
1846
-
1847
-
1848
Mode separation results of different methods in Qingdao shallow sea waveguide conditions.
منشور في 2025الموضوعات: -
1849
-
1850
Results of different Warping transform corrections for negative sound velocity gradient profiles.
منشور في 2025الموضوعات: -
1851
Mode separation results of different methods in Qingdao shallow sea waveguide conditions.
منشور في 2025الموضوعات: -
1852
-
1853
-
1854
Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf
منشور في 2025"…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …"
-
1855
Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf
منشور في 2025"…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …"
-
1856
Data Sheet 1_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf
منشور في 2025"…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …"
-
1857
-
1858
-
1859
-
1860